Thin
Discover high-purity clinical-grade APIs, incretin analogues, and specialized host-defense peptide sequences manufactured under stringent E-E-A-T and cGMP-compliant systems.
Addressing the silent pandemic of Antimicrobial Resistance (AMR) through disruptive biomolecular architectures, scalable solid-phase synthesis, and bio-engineered host defense peptides.
The global healthcare infrastructure faces an acute existential threat from multidrug-resistant pathogens (ESKAPE pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). Traditional small-molecule antibiotics, which typically act on specific metabolic enzymes or single-target intracellular proteins, induce high evolutionary selective pressures that facilitate rapid target mutation, plasmid-mediated gene transfer, and efflux-pump over-expression.
In contrast, Anti-Microbial Peptides (AMPs)—also referred to as host defense peptides (HDPs)—function through non-specific biophysical membrane destruction. Endowed with amphipathic alpha-helical or beta-sheet conformations, cation-rich AMP sequences interact electrostatic-mechanically with negatively charged bacterial membranes (lipopolysaccharides in Gram-negative bacteria and teichoic acids in Gram-positive bacteria). By executing membrane permeabilization via barrel-stave, carpet, or toroidal-pore mechanisms, AMPs dramatically lower the emergence frequency of microbial resistance, making them prime pharmaceutical alternatives.
Historically, the widespread commercial deployment of peptide antibiotics has been constrained by elevated cost-of-goods-sold (COGS), metabolic proteolytic vulnerability, and systemic hemolytic cytotoxicity. Recombinant expression platforms frequently suffer from peptide self-toxicity toward host expression vectors, erratic inclusion body isolation, and low recovery yields.
Hangzhou Thinheal Pharma-Tech solves this commercial bottleneck by combining high-efficiency Solid-Phase Peptide Synthesis (SPPS) with microwave-assisted coupling, automated real-time axial solvent monitoring, and continuous green-solvent recycling. By engineering non-natural D-amino acid substitutions, peptide cyclization, and fatty acid conjugation (lipidation), we extend in-vivo metabolic half-lives while systematically minimizing mammalian hemolytic profiles—delivering multi-ton manufacturing capability tailored for worldwide bulk API demands.
Tailored biochemical modifications optimized for pharmaceutical pipelines, clinical wound therapeutics, veterinary health, and sterile cosmetic bio-preservation.
Systemic and topical treatments formulated for chronic diabetic ulcers, severe burn infections, and biofilm-eradication on surgical sites. Designed with low human cell cytotoxicity and potent rapid bactericidal kill kinetics.
Eco-friendly, non-toxic antibiotic alternatives to prevent porcine enteric colibacillosis and poultry necrotic enteritis. Resistant to digestive proteases via N-terminal acylation and cyclic backbones.
Clean-label bio-active peptides providing dual functions: eliminating cutaneous Cutibacterium acnes while acting as self-preserving biological stabilizers without synthetic parabens.
From computational sequence design to full commercial-scale multi-kilogram isolation, our CDMO infrastructure ensures reproducibility and complete regulatory compliance.
Machine learning-assisted sequence optimization for balancing net positive charge (+2 to +9) with ideal amphipathic moments, eliminating hemolytic motifs before synthesis commences.
Automated Fmoc/tBu solid-phase synthesis featuring continuous acoustic monitoring. Prevents peptide aggregation during difficult sequence assembly of highly hydrophobic segments.
Dual-phase reverse chromatography paired with ion-exchange systems to systematically remove closely related diastereomers, truncation sequences, and polymeric impurities.
Full batch release documentation including RP-HPLC purity traces, high-resolution ESI-MS molecular weight confirmation, net peptide content, counter-ion quantification, and endotoxin assay.
Explore our expanded synthesis portfolio spanning metabolic modulators, neuro-protective peptides, cardiovascular peptides, and targeted hormonal analogues.
Detailed answers addressing peptide stability, counter-ion exchanges, analytical characterization, and commercial CDMO transfer parameters.
AMP sequences are inherently prone to synthetic difficulties because they possess high ratios of positively charged residues (Lys, Arg) coupled with strongly hydrophobic hydrophobic domains (Trp, Phe, Leu), causing on-resin hydrophobic stacking and incomplete acylation. Thinheal integrates proprietary microwave-assisted peptide synthesis, dynamic pseudo-proline dipeptide building blocks, and optimized cleavage-cocktail strategies that achieve high raw crude purities (>85%), substantially decreasing preparative purification loss and lowering commercial manufacturing costs.
Our formulation and medicinal chemistry teams engineer peptide scaffolds through D-amino acid substitution, terminal capping (N-terminal acetylation, C-terminal amidation), retro-inverso transformations, and side-chain cyclization (lactam bridges, disulfide staples). These conformational constraints protect the peptide bond against systemic aminopeptidases and endopeptidases while optimizing the therapeutic index (TI)—maximizing bacterial membrane selectivity over mammalian erythrocyte membranes.
Yes. Crude peptides cleaved from standard resins naturally contain residual TFA salts, which are cytotoxic to mammalian cells and bias in-vitro MIC assays. We provide validated counter-ion exchange protocols, replacing TFA with pharmaceutical-grade acetate (AcO-) or hydrochloride (HCl) salts, systematically lowering residual TFA below 0.5% or non-detectable levels with rigorous ion-chromatography verification.
Every commercial or research batch is accompanied by an itemized Certificate of Analysis (CoA) including: (1) RP-HPLC purity profiles, (2) High-resolution Mass Spectrometry (HRMS) verifying exact monoisotopic or deconvoluted mass, (3) Karl Fischer moisture testing, (4) Amino Acid Analysis (AAA) for Net Peptide Content calculation, (5) Residual solvent clearance by Headspace GC, and (6) Chromogenic LAL testing for bacterial endotoxins (<0.05 EU/mg for preclinical/clinical grades).
Our multi-ton annual capacity facility in Hangzhou houses solid-phase reactors ranging from 5L to 1000L glass-lined vessels. We seamlessly scale peptide projects from early-stage milligram lead discovery batches up to multi-hundred-kilogram commercial production campaigns with established process analytical technology (PAT) and full CMC technical dossier support.